News
Public · Published
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
Moderna said initial data from its ongoing Phase 1/2 trial of experimental mRNA-2808 will be presented orally at the American Society of Hematology meeting on December 12–15, 2026. Among 11 evaluable patients with relapsed or refractory multiple myeloma, four responses were confirmed; no dose-limiting toxicities or treatment-related serious adverse events were observed.
Published:
Updated:
What happened
Moderna said initial data from its ongoing Phase 1/2 trial of experimental mRNA-2808 will be presented orally at the American Society of Hematology meeting on December 12–15, 2026. Among 11 evaluable patients with relapsed or refractory multiple myeloma, four responses were confirmed; no dose-limiting toxicities or treatment-related serious adverse events were observed.
Confirmed
Global impact / market context
The responses and evidence that all three engineered proteins were produced in patients offer an early sign that the treatment approach is biologically active. If later studies confirm benefit and safety, mRNA-2808 could support future revenue, but these early results do not establish effectiveness or approval.
Analyst inference
The report concerns a small, early-stage study in patients whose cancer had returned or resisted treatment, so the findings are preliminary rather than proof of broad benefit. The December presentation may provide more detail, while development costs and clinical uncertainty remain relevant to Moderna’s investment outlook.
Analyst inference
What to watch
- At the December 12–15 ASH meeting, watch for fuller trial results, including response durability and safety details; the supplied report gives only initial findings and a partial safety account. Analyst inference
- Further trial updates could clarify whether responses persist and whether side effects remain manageable, helping determine if Moderna should continue investing in larger studies of mRNA-2808. Analyst inference
- The report states that four of 11 evaluable patients responded and that all three encoded T-cell engagers were detected in plasma, with exposure rising across dose levels. Confirmed